1. General picture: Getting closer to target treatment

In recent years, research on facial–shoulder–arm dystrophy (FSHD) has made remarkable progress.

Previously, FSHD was consideredcannot be completely treated, but now:

• Scientists have clearly determinedDUX4 gene is the main cause of the disease
• Many treatment approaches are being developedTurn off or control DUX4
• Several therapies have stepped inclinical trials on humans

👉 This means:We are moving from "understanding the disease" to "treating intervention"

---

2. Main treatment research directions

🔬 2.1. Therapy "turns off the DUX4 gene"

This is the most important direction today.

Objective:

• Prevents the DUX4 gene from functioning abnormally in the muscle

Technologies being researched:

• Antisense oligonucleotide (ASO): RNA blocking of DUX4
• RNA interference (RNAi): “silencing” disease-causing signals
• CRISPR-based therapy: gene expression editing

👉 If successful, this could be itdisease-modifying therapy

---

💉 2.2. Biological & Antibody Therapies

Some growing companies:

• Biological drugs aimreduced toxicity caused by DUX4
• Antibodies helpProtect muscle cells

Some drug candidates have:

• Enterclinical trials
• Evaluatingsafety and effectiveness

---

🧪 2.3. Muscle strengthening & symptom relief therapy

In parallel with gene treatment, research also focuses on:

• Reduce muscle inflammation
• Increase muscle strength
• Improve motor function

Includes:

• Muscle metabolism drugs
• Combined rehabilitation therapy

👉 Here is a guide to helpImprove quality of life while waiting for specific treatment

---

🧬 2.4. Biomarkers

Another important advance is:

• Find out thebiomarkerto monitor disease

For example:

• Blood test
• Muscle MRI
• Measure motor function

👉 Help:

• Evaluate disease progression more accurately
• Speed up the drug testing process

---

3. Clinical trials are ongoing

According to updates from the international community:

• Many trials are taking place in the US, Europe and Australia
• Some studies have been carried outstages 2 and 3

Main goals:

• Evaluate drug effects on muscles
• Measures ability to improve movement
• Check for long-term safety

👉 This is an extremely important stage to move forwardfuture drug approvals

---

4. The role of the patient community

Organizations such asMyFSHDandFSHD Global Research Foundationemphasis:

Patients play a key role in research:

• Participate in patient data registration
• Participate in clinical trials
• Share disease progression information

👉 The more data → the faster the research → the sooner the drug is released